Digistain Presents Key Research Findings at the San Antonio Breast Cancer Symposium

Onco:Innovate partner Digistain presented two compelling abstracts at the prestigious San Antonio Breast Cancer Symposium 2024, marking a significant milestone in the advancement of breast cancer diagnostics.

The first abstract shared groundbreaking head-to-head data from Charing Cross Hospital, comparing the predictive accuracy of Digistain against Oncotype DX for metastasis-free survival. This study, which represents part of a larger multi-centre effort, underscores the promise of Digistain as a powerful tool in predicting patient outcomes. Notably, these findings will be part of an upcoming publication set for release early next year, offering further insights into the potential of Digistain in clinical practice.

The second abstract focused on evaluating the robustness of Digistain by testing its performance against variations in tissue fixation time. This study highlights the technology’s reliability in real-world clinical settings, where tissue handling conditions can often vary. By demonstrating Digistain’s consistent accuracy despite these variations, the results reinforce its practical utility in diverse clinical environments.

These exciting developments mark an important step forward for Digistain, as the company continues to push the boundaries of breast cancer diagnostics. With a commitment to providing faster, more cost-effective solutions, Digistain is poised to empower clinicians and improve outcomes for patients worldwide.

As breast cancer treatment evolves, the ability to accurately predict metastasis-free survival and adapt diagnostic tools to real-world conditions is more critical than ever. Digistain’s ongoing innovations demonstrate its potential to reshape the landscape of breast cancer diagnostics, making these tools more accessible, reliable, and efficient for healthcare professionals around the globe.

For more information about the abstracts presented at the San Antonio Breast Cancer Symposium, visit the official SABCS website: https://sabcs.org/Call-for-Abstracts-2024.

The presented abstracts include:

• P1-11-27: Comparative Evaluation of Digistain and Oncotype DX in Predicting Metastasis-Free Survival in Early Stage Hormone-Receptor Positive Breast Cancer: A Randomized Study at Charing Cross Hospital
  
• P4-07-29: Analytical Validity of the Digistain Test in the Face of Variable Fixation Times: A Study from Charing Cross Hospital

With these recent accomplishments, Digistain continues to make strides in revolutionizing the way breast cancer is diagnosed and treated globally.

Digistain CEO Dr.Hemmel Amrania will be a keynote speaker at the Onco:Innovate conference 2025 in Vienna. Don’t miss it!